Testosterone safe for heart in hypogonadism

The European Medicines Agency (EMA) reviewed the medical literature and post-marketing surveillance data after recent studies suggested an increased risk in cardiovascular events, particularly myocardial infarction, in men being treated with testosterone.

However, the review found the evidence was “inconsistent” and a regulatory body representing EU Member States, the CMDh, agreed with the conclusion by consensus.

“Taking all the data into account, the signal for an increased cardiovascular risk